Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Colorectal Neoplasms 8Venous Thromboembolism 4Polycythemia Vera 3Prostatic Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Fallopian Tube Neoplasms 2Colorectal Neoplasms, Hereditary Nonpolyposis 2Breast Neoplasms 2Thrombocythemia, Essential 1Testicular Neoplasms 1Smoking Cessation 1Sarcoma 1Primary Myelofibrosis 1Ovarian Neoplasms 1Ovarian Cancer Prevention 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Motor Activity 1Lung Neoplasms 1Liver Cirrhosis 1Leukemia, Hairy Cell 1Inflammation 1Hemorrhage 1Hematoma 1Fibrosis 1Endometrial Neoplasms 1Colorectal Neoplasia 1

Interventions

fludarabine 19Whole-Body Irradiation 18Cyclophosphamide 17fludarabine phosphate 16ruxolitinib 15Mycophenolic Acid 14Specimen Handling 13Tacrolimus 11Azacitidine 11Biopsy 10Peripheral Blood Stem Cell Transplantation 9Melphalan 9Cytarabine 9venetoclax 8Sirolimus 8Busulfan 8Stem Cell Transplantation 6Injections 6Granulocyte Colony-Stimulating Factor 6Daunorubicin 5Cyclosporine 5CPX-351 5luspatercept 4ivosidenib 4itacitinib 4fedratinib 4decitabine and cedazuridine drug combination 4Thiotepa 4Liposomes 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Aspirin × 1 year × Clear all
NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

PharmaEssentia Japan K.K.

Phase 2 Completed
29 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06290765 2025-07-31

PV

PharmaEssentia

Phase 4 Not yet recruiting
70 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡